Tumor Molecular Imaging with Nanoparticles

Zhen Cheng , Xuefeng Yan , Xilin Sun , Baozhong Shen , Sanjiv Sam Gambhir

Engineering ›› 2016, Vol. 2 ›› Issue (1) : 132 -140.

PDF (2399KB)
Engineering ›› 2016, Vol. 2 ›› Issue (1) :132 -140. DOI: 10.1016/J.ENG.2016.01.027
Research
Research

Tumor Molecular Imaging with Nanoparticles

Author information +
History +
PDF (2399KB)

Abstract

Molecular imaging (MI) can provide not only structural images using traditional imaging techniques but also functional and molecular information using many newly emerging imaging techniques. Over the past decade, the utilization of nanotechnology in MI has exhibited many significant advantages and provided new opportunities for the imaging of living subjects. It is expected that multimodality nanoparticles (NPs) can lead to precise assessment of tumor biology and the tumor microenvironment. This review addresses topics related to engineered NPs and summarizes the recent applications of these nanoconstructs in cancer optical imaging, ultrasound, photoacoustic imaging, magnetic resonance imaging (MRI), and radionuclide imaging. Key challenges involved in the translation of NPs to the clinic are discussed.

Keywords

Tumor / Molecular imaging / Nanoparticles

Cite this article

Download citation ▾
Zhen Cheng, Xuefeng Yan, Xilin Sun, Baozhong Shen, Sanjiv Sam Gambhir. Tumor Molecular Imaging with Nanoparticles. Engineering, 2016, 2(1): 132-140 DOI:10.1016/J.ENG.2016.01.027

登录浏览全文

4963

注册一个新账户 忘记密码

Introduction

Cancer is now the leading cause of death in the world [ 1]. China constitutes approximately 20% of the world’s population, and comprises 29.42% of new cancer cases and 27% of cancer deaths worldwide. In 2012, the cancer incidence rate in China was 1.74%, and the cancer mortality rate was 1.22%. In China, cancers of the stomach and liver have traditionally occurred with the highest frequency; however, the incidence of lung cancer has increased as the leading cause of cancer in recent years [ 2]. Despite the fact that huge advances in diagnostic technologies have led to an explosion of knowledge in cancer research, only a minute number of cancer patients are diagnosed at early stages due to the poor selectivity and sensitivity of conventional diagnostic techniques.

Traditional imaging technologies reflect mostly anatomical changes that differentiate pathological from normal tissue rather than measuring the biological processes responsible for disease. Molecular imaging (MI) is a rapidly emerging biomedical research method that enables visual representation, characterization, and quantification of biological processes at the cellular and/or molecular level within living organisms [ 3− 5]. Several MI modalities are currently available, including fluorescence and bioluminescence imaging, targeted ultrasound (US), molecular magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), single-photon-emission computed tomography (SPECT), and positron emission tomography (PET). Probes or beacons, which can accumulate at the site of interest and allow for imaging, are required for MI. However, the limitations of some MI techniques include poor spatial resolution, low sensitivity, or poor signal penetration through tissues. For example, optical imaging is restricted in its depth-penetration capability, leading to poorer resolution, whereas MRI can image deep tissues but is much less sensitive (Table 1).

Nanoparticles (NPs) are emerging as a new class of MI agent to overcome these major hurdles in detecting human disease. NPs have great potential for accurate cancer diagnosis via passive accumulation and/or active-targeting approaches [ 6]. Combining their large payload-carrying capacity, high signal intensity, and stability, NPs can deliver high concentrations of imaging agents to the target region. NPs are typically smaller than cells [ 7], and are comparable in size to molecules and proteins [ 8].

Historically, many of the developed NPs are considered to accumulate in tumors based on the enhanced permeability and retention (EPR) effect, which in nanomedicine research has been considered a universal feature of solid malignant tumors that can serve as the basis for passive tumor-targeting by therapeutic and diagnostic NPs [ 9− 17]. The EPR effect was first reported as a concept of the delivery of macromolecular drugs to tumors [ 18]. However, the heterogeneity of the EPR effect provoked a debate about the real value of this effect. Many experimental scientists, pharmacologists, and nanotechnology engineers hold to the premise that solid tumors consist of uniform tissue; that is, that tumors are homogeneous [ 19]. However, as this is not the case, new strategies such as active targeted NPs have been pursued. Targeted NPs can perform with both high sensitivity and specificity to achieve high accumulation at the tumor site [ 20− 23]. Active targeting requires the therapeutic agent to be guided to the target by conjugating the therapeutic agent or carrier system to a tissue or cell-specific ligand. In addition, using targeted NPs with a variety of moieties to reach multiple binding sites can provide higher binding efficiencies for targeting specific tumor sites.

A number of articles review the current applications of nanotechnologies for MI [ 24]. This paper presents a brief overview of recent developments in nanotechnology for MI, and will also address the drawbacks and future challenges of current nanoplatforms for the clinical translation of imaging.

Nanoplatforms

A wealth of NP-based systems exploits nanoplatforms for many imaging modalities. These NPs come in a wide variety of compositions, sizes, shapes, and structures from a variety of materials [ 25, 26]. These different materials and shapes range from spheres, rods, and cubes to resembling snowflakes, flowers, thorns, hemispheres, worms, discoids, and chains−a wide variety that enables many imaging modalities (e.g., optical imaging, MRI, US, and/or nuclear imaging) for combining disease diagnosis and therapy into so-called “theranostic” (therapy plus diagnostic) applications. As mentioned earlier, NPs have been known to target tumors via passive- and/or active-targeting pathways. Due to abnormally leaky vasculature and the lack of an effective lymphatic drainage system in tumor tissues, NP platforms can passively accumulate in tumor tissues. These unique phenomena are jointly referred to as the EPR effect. Moreover, NPs can recognize, bind to, and internalize into tumor cells via receptor-mediated endocytosis when modified with tumor-targeting moieties such as antibodies, nucleic acids, proteins, or other ligands. In this section, we will describe exemplary theranostic nanoplatforms along with their applications regarding cancer.

Optical nanoparticles

Optical imaging offers high sensitivity, cost-effectiveness, non-ionizing radiation, and great potential for small-animal studies. However, the penetration depth of light prohibits deep-tissue imaging and is the major disadvantage for in vivo imaging in humans; thus, optical imaging is typically not quantitative for living-subject imaging studies. An abundance of probes, including synthetic fluorophores, semiconductor fluorescent crystals, and probes based on lanthanide rare-earth ions, have been developed for small-animal imaging [ 27− 29].

Quantum dots (QDs) are the most widely studied NPs for preclinical optical imaging applications. Compared with organic fluorophores, QDs possess many superior properties for biological imaging, such as a strong resistance to photobleaching and chemical degradation, high quantum yields, continuous absorption spectra from ultraviolet (UV) to near-infrared (NIR), and large effective Stokes shifts [ 30− 33]. Arginine-glycine-aspartic acid (RGD)-QDs could selectively bind to luminal endothelium in mouse tumor neovasculature [ 34]. However, because of their small size, QDs demonstrated poor retention inside the tumor, easily washing back out into the bloodstream [ 33] (Fig. 1). Nevertheless, the major drawbacks for the clinical utility of QDs are their potential toxicity and lack of deep-tissue imaging and quantification ability [ 35]. With the help of small-animal PET, radiolabeled QDs were found to have rapid uptake into the reticuloendothelial system (RES), liver, and spleen [ 36, 37]. In order to reduce the uptake of QDs into the RES, human serum albumin (HSA) was explored as a coating for QD800-mercaptopropionic acid (MPA) NPs. The resulting QD800-MPA-HSA NPs show reduced localization in mononuclear phagocytic system-related organs over QD800-MPA, plausibly due to the low uptake of QD800-MPA-HSA in macrophage cells. QD800-MPA-HSA may have great potential for in vivo fluorescence imaging [ 38]. Affibody-modified QDs also showed high specificity for targeting human epidermal growth factor receptor 2 (HER2)-expressing cells and tumors [ 39].

Dyes that can be incorporated or encapsulated in polymeric NPs include indocyanine green (ICG) [ 40], NIR region fluorescent cyanine 7 (Cy7) [ 41], and dialkylcarbocyanine fluorophores [ 42], which have been approved by the United States Food and Drug Administration (FDA). A nanoplatform strategy is a promising method to enable optical imaging to overcome the drawbacks of free and small dyes [ 43, 44]. Various nanocarriers have been investigated for the delivery of NIR dye to tumor sites, including liposomes, silica, polymersomes, and targeted rare-earth nanocrystals [ 45].

To overcome the light penetration issue and realize deep-tissue imaging, radiation-luminescence-excited fluorophores such as QDs can be used for in vivo multiplexed optical imaging by mimicking a natural bioluminescence resonance energy transfer (BRET) process, in which chemical energy is converted into photons to excite the QDs [ 46]. Photocaged upconversion nanoparticles (UCNPs) take advantage of the photon upconversion of NIR light to UV light to trigger the uncaging of D-luciferin from D-luciferin-conjugated UCNPs. The released D-luciferin effectively confers enhanced fluorescence and bioluminescence signals in vitro and in vivo, with deep light penetration and low cellular damage [ 47].

Cerenkov luminescence imaging is an emerging imaging modality, similar to bioluminescence imaging, which captures visible photons emitted by Cerenkov radiation [ 48]. Radioluminescent nanophosphors (RLNPs) have been proposed as MI probes in the development of combined X-ray/optical imaging modalities, such as X-ray luminescence computed tomography (XLCT) [ 49− 51]. PEGylated Eu3+-doped nanophosphors under biological conditions were shown to emit luminescence under excitation by either 18F radioisotope or X-rays. This capability provides the potential to enable novel imaging modalities, such as XLCT or deep-tissue Cerenkov luminescence imaging [ 52].

Raman spectroscopy is based on the light-scattering phenomenon, as opposed to the absorption/emission in fluorescence, and Raman active molecules are more photostable than fluorophores, which are rapidly photobleached. Surface-enhanced Raman spectroscopy (SERS), active NPs, and single-wall nanotubes (SWNTs) can be used for noninvasive imaging in small living subjects by using Raman spectroscopy [ 53, 54]. Affibody-functionalized gold silica NPs performed Raman MI of the epidermal growth factor receptor in a colon cancer mouse model [ 55].

Photoacoustic imaging (PAI) is a new hybrid biomedical imaging modality related to optical imaging, which has the potential for both functional and anatomic imaging [ 56]. The generated ultrasonic waves are detected by ultrasonic transducers and then analyzed to produce images. However, exogenous contrast agents are needed for MI, due to the differences in the absorption spectra of different tissues [ 57]. Non-plasmonic or plasmonic NPs, such as gold nanoshells, nanorods, or nanocages, can promote light absorption, improving the contrast of PAI signals [ 58]. Perylene-diimide (PDI)-based NIR-absorptive organic NPs (micelle-enveloped PDI) are an efficient contrast agent for the PAI of deep brain tumors in living mice. By encapsulating them into amphiphilic molecules, water-soluble PDI NPs were easily synthesized and exhibited excellent PAI properties [ 59]. PAI of targeted SWNTs may contribute to the noninvasive cancer imaging and monitoring of nanotherapeutics in living subjects [ 60− 63]. Melanin nanoparticle (MNP) is another biopolymer with good biocompatibility and biodegradability, intrinsic photoacoustic (PA) properties, and binding ability to drugs, as an efficient endogenous nanosystem for imaging-guided chemotherapy [ 64, 65]. Sorafenib (SRF) is chosen for constructing PEGylated-melanin-drug system. SRF-PEG-MNPs were labeled with 64Cu and used to perform a PET/PAI dual modalities imaging-guided therapy [ 66]. By embedding ultrasmall MNPs into the cavities of apoferritin (APF), nanomaterials apoferritin-melanin-Fe (AMF) NPs with core-shell structures can easily load 64Cu2+ and Fe3+ to achieve trimodal (PET/MRI/PAI) imaging [ 67] (Fig. 2).

Ultrasound agents

US has excellent spatial resolution and contrast sensitivity. Due to its low cost and wide availability, US is the most commonly used clinical imaging modality [ 68]. Its use is limited in the imaging of some organs, such as lungs. Nanoscale US agents have been reported in the past decade [ 69, 70]. A strategy to improve the in vivo half-life of US agents has been explored by targeting vascular markers of tumor angiogenesis [ 71]. While there have been recent examples of nanoscale US agents, due to the short in vivo half-life of US agents, the vast majority of targeted agent development has focused on seeking vascular markers of tumor angiogenesis. Anderson et al. [ 72] modified the surface of microbubbles (MBs) with cRGD ligand and then showed that these exhibit five-fold higher adhesion to immobilized recombinant αvβ3 integrin, compared with control groups. Yan et al. [ 73] synthesized iRGD-lipopeptides into an MB membrane. The binding specificity of iRGD-MBs for endothelial cells was found to be significantly stronger than that of control MBs under in vitro static and dynamic conditions. Furthermore, many peptides have been developed as ligands to direct MBs to integrins. Willmann et al. [ 74] designed MBs with engineered cystine knot (knottin) peptides, a new class of targeting ligands to αvβ3 integrin, for targeted contrast-enhanced US imaging of tumor angiogenesis. MB-KnottinIntegrin attached significantly more to αvβ3 integrin positive cells than to control cells. In addition to integrins, the expression of vascular endothelial growth factor receptor 2 (VEGFR2) is another target of interest for imaging and monitoring during treatment. Contrast agent MBs for dual-targeting imaging can be modified to attach to both VEGFR2 and αvβ3 integrin [ 75]. As a result of the increased avidity that comes from the multi-ligand approach, the dual-targeting US MBs exhibited significantly higher signal compared with the single-targeting counterparts.

Magnetic nanoparticles

MRI is a noninvasive diagnostic technique providing superb image resolution and exquisite soft-tissue contrast for anatomical details. A considerable amount of work has been done in the development of MRI NPs, and especially with iron oxide NPs (IONPs). This is an important class of nanoplatform with the advantages of high sensitivity, shortened T1 and T2 relaxation times in a dose-dependent manner, and the versatility to present a wide variety of ligands for cellular and molecular imaging. There are more than 20 current clinical trials of superparamagnetic iron oxide (SPIO) or ultrasmall superparamagnetic iron oxide (USPIO). The iron oxide NPs are usually taken up by the RES [ 76], which also permits liver [ 77− 79], spleen [ 80], and lymph node imaging. The accumulation of these NPs at the tumor site is based on the EPR effect due to the presence of leaky vasculature as well as uptake by macrophages.

IONPs such as SPIO NPs have been extensively studied for tumor-targeting probes due to their excellent biocompatibility [ 10]. The synthesis process for these particles ranges from traditional wet chemistry solution-based methods to more exotic techniques [ 81, 82]. The field of magnetic NP probe technology has recently been promoted by efforts devoted to developing its potential as an important tool for efficient cross-application MI [ 83]. Hybrid nanotrimers performed dual T1- and T2-weighted MRI with high accuracy and reliability, as revealed by a PET imaging study, and displayed favorable biodistribution and suitability for in vivo imaging [ 84] (Fig. 3).

Research with SPIO NPs has already demonstrated their utility as an important tool for enhancing magnetic resonance (MR) contrast [ 85]. It is desirable for the NPs used for this application to have high magnetization values and a size smaller than 100 nm, with a narrow particle-size distribution [ 86]. Magnetic NPs offer a number of advantages, including laser-induced thermal therapy, the ability to target specific sites, and relatively low toxicity [ 87]. Biological applications of magnetic NPs also require magnetic particles to have a special surface coating that must be nontoxic and biocompatible, and that must permit targetable delivery with particle localization in a specific area. Such magnetic NPs can be easily conjugated to drugs, proteins, enzymes, antibodies, or nucleotides and can be directed to an organ, tissue, or tumor using an external magnetic field.

The specific structure of dendrimers makes them an attractive NP platform for gadolinium (Gd)-loading due to their narrow size distribution (5−10 nm); branched structure, which facilitates the presentation of multiple ligands or contrast agents; and associated renal clearance. For example, Gd-loaded dendrimers targeting the folate receptor displayed enhanced MR signal in an animal model of a κB-tumor. When designing Gd-based agents, several factors need to be considered, since signal intensity at the target site is not linearly related to the concentration of the imaging moiety. For example, the intracellular accumulation of Gd can markedly impact signal intensity. Furthermore, the presence of Gd atoms in an NP structure also impacts the efficiency of NP MR probes.

Nanoparticles for nuclear imaging

With the development of the micro scanner contributing to small-animal imaging, nuclear imaging can be performed with low mass amounts to measure the function of biological processes [ 88]. With high contrast sensitivity, PET imaging plays an important role in MI, albeit with the disadvantage of low resolution. Based on existing knowledge of nuclear imaging with small molecules, NP-based nuclear imaging agents have been rapidly developed. During the past decade, there have been various reports on PET imaging with targeted NPs. The most common way to integrate PET imaging capability into NPs is to attach a radiometal (e.g., 64Cu) via a metal chelator, such as 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) or 1,4,7-triazacyclononane-N,N′,N′′-triacetic acid (NOTA). After purification, NPs radiolabeled with 64Cu can reach greater than 95% radiochemical purity [ 89− 91].

Since no single modality is perfect and sufficient to obtain all necessary information, several other NP platforms have been investigated for the development of multimodal contrast agents, such as for use with combined PET and optical imaging, or PET and MRI. Multimodal imaging enables the use of PET for treatment planning with whole-body imaging, and the use of optical techniques during therapeutic intervention. Cai et al. [ 92] developed a near-infrared fluorescence (NIRF) imaging and PET imaging agent based on QD. RGD peptides were modified on the surface of QDs, allowing them to target the αvβ3 integrin. At the same time, DOTA was also conjugated for 64Cu labeling. This dual-modality probe sufficiently improves tumor contrast while decreasing the dose required for in vivo NIRF imaging, thus leading to a significant reduction in the potential toxicity of QDs [ 93, 94]. Similarly, Chen et al. [ 95] synthesized a 64Cu-DOTA-QD-VEGF nanoprobe to primarily target the vasculature through a VEGF-VEGFR interaction. Nahrendorf et al. [ 96, 97] synthesized a dextran-coated SPIO NP co-labeled with 64Cu and an NIR fluorophore (VivoTag 680), which can perform both fluorescence molecular tomography (FMT) and PET imaging of tumor-associated macrophages. Yang et al. [ 98] modified a multimodal RGD-targeted SPIO. After labeling with 64Cu, the NPs can be used for monitoring drug delivery to solid tumors through PET/MR dual-modal imaging [ 98]. As a photosensitizer, porphyrin not only provides photodynamic ability but also serves as a promising dye for fluorescent imaging. Liu et al. [ 99] developed a 64Cu-porphorysome nanoplatform presenting the ability to detect small bone metastases in lower limbs through optical-PET dual-modal imaging. Chen et al. [ 100] recently investigated targeted hollow mesoporous silica NPs (HMSNs) for PET/optical imaging of tumor angiogenesis by using CD105. They demonstrated a three-fold higher accumulation compared with their non-targeted group [ 100] (Fig. 4). Liu et al. [ 61] investigated integrin-targeted SWNTs, which performed remarkable dual Raman and PET tumor-targeting imaging. Zirconium-89 (89Zr) is a new and promising PET radionuclide for in vivo studies [ 101− 105]. Ruggiero et al. [ 106] developed antibody-labeled 89Zr-SWNT, which targeted the monomeric vascular endothelial-cadherin (VE-cad) epitope with monitoring by PET and NIRF imaging. Using this nanoplatform, the tumor angiogenesis can be estimated. Lee et al. [ 107] monodispersely synthesized polymer-coated UCNPs and dimeric RGD-conjugated UCNPs. This NP platform can be used for optical imaging, MRI, and PET, with highly selective targeting to αvβ3 integrin [ 107]. Lijowski et al. [ 108] designed T1-based αvβ3-targeted 99mTc-Gd NPs, which produced high sensitivity and specific localization of tumor angiogenesis by SPECT-MR imaging [ 108]. Hu et al. [ 109] investigated 111In-perfluorocarbon modified by αvβ3 integrin, producing a multimodal PET-MR agent. Radiolabeling Ac-Cys-ZEGFR:1907-modified Au-IONP (NOTA-Au-IONP-affibody) with PET radionuclide, 64Cu, resulted in an epidermal growth factor receptor (EGFR)-targeted PET/optical/MR imaging probe, 64Cu-NOTA-Au-IONP-affibody, targeted toward EGFR-positive tumors [ 110].

Challenges and future perspectives

Some fundamental hurdles hamper the approval of NPs for clinical use; these hurdles correlate to various materials characteristics including size, shape, composition, single crystallinity, and magnetism. The first hurdle is that of delivery obstacles. In particular, the RES can phagocytose the NPs, rapidly sweeping them out of blood circulation and accumulating them in the liver, spleen, and bone marrow. This phenomenon gives cause to further toxicity concerns. The toxicity of NPs is another very important hurdle. Toxicity can result not only from concentration in the bone marrow and other organs but also from the composition of the NPs themselves, such as the Cd used in QDs and other coating materials. Additional hurdles include the inability to overcome certain biological barriers, such as the blood-brain barrier (BBB), as well as the lack of control over the distribution of NPs following administration. The fate of NPs after their intravenous administration is highly variable and dependent on their size, morphology, charge, and surface chemistry. An NP size of below 100 nm is often used in order to increase effectiveness and blood-circulation time, for adequate exposure to the tumor and drug release.

Given these existing hurdles, next-generation platforms will likely emphasize the development of small-size NPs, their high colloidal composition, and bio-stability. Significant improvements in sensitivity and target specificity are expected, which will bring huge advancements in current cancer-diagnostic capabilities. Additional regulatory and development considerations will arise when future generic nanomedicines are presented for health authority (FDA) approval with claims of equivalence to the innovator drug. In addition, in the face of the natural biological barriers to the delivery of nanomedicines, tissues with aberrant pathology, such as tumors, are often very efficient in harnessing active biological mechanisms for high nutrient supply and rapid growth. Elucidation of these active transport mechanisms and the ability to harness them with nanomedicines could provide a step forward in the treatment of cancer and other diseases.

Conclusions

Over the last decade, the field of nanotechnology has experienced tremendous growth and advancement. With substantial efforts by both researchers and the biopharmaceutical industry, a few nanomedicines have already been successfully approved for preclinical and clinical studies. However, the field of nanomedicine is still in its early stages due to unfamiliar types of risk in safety and efficacy that require further discussion and cooperation among researchers and governmental agencies. The challenges in developing NPs for use in MI may be overcome in the near future.

Compliance with ethics guidelines

Zhen Cheng, Xuefeng Yan, Xilin Sun, Baozhong Shen, and Sanjiv Sam Gambhir declare that they have no conflict of interest or financial conflicts to disclose.

References

Publishing order | Descend order by publishing year | Descend order by cited within
[1]

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin2015; 65(2): 87−108.
[2]

Yu S, Yang CS, Li J, You W, Chen J, Cao Y, Cancer prevention research in China. Cancer Prev Res (Phila)2015; 8(8): 662−74.
[3]

Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med2002; 8(8): 891−7.
[4]

Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev2003; 17(5): 545−80.
[5]

James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev2012; 92(2): 897−965.
[6]

Koo H, Huh MS, Sun IC, Yuk SH, Choi K, Kim K, In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res2011; 44(10): 1018−28.
[7]

Wiwanitkit V. Glomerular pore size corresponding to albumin molecular size, an explanation for underlying structural pathology leading to albuminuria at nanolevel. Ren Fail2006; 28(1): 101.
[8]

Ullman EF, Schwarzberg M, Rubenstein KE. Fluorescent excitation transfer immunoassay. A general method for determination of antigens. J Biol Chem1976; 251(14): 4172−8.
[9]

Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med2008; 59: 251−65.
[10]

Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer2005; 5(3): 161−71.
[11]

Lammers T. Drug delivery research in Europe. J Control Release2012; 161(2): 151.
[12]

Brambilla D, Luciani P, Leroux JC. Breakthrough discoveries in drug delivery technologies: the next 30 years. J Control Release2014; 190: 9−14.
[13]

Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release2012; 164(3): 265−75.
[14]

Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev2013; 65(1): 71−9.
[15]

Altundag K, Dede DS, Purnak T. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma. J Clin Pathol2007; 60(8): 958.
[16]

Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res2006; 12(5): 1570−6.
[17]

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release2000; 65(1−2): 271−84.
[18]

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res1986; 46(12 Pt 1): 6387−92.
[19]

Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev2015; 91: 3−6.
[20]

Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res2011; 44(10): 1094−104.
[21]

Ambrogio MW, Thomas CR, Zhao YL, Zink JI, Stoddart JF. Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res2011; 44(10): 903−13.
[22]

Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res2011; 44(10): 936−46.
[23]

Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res2011; 44(10): 875−82.
[24]

Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin2013; 63(6): 395−418.
[25]

Piner RD, Zhu J, Xu F, Hong S, Mirkin CA. “Dip-Pen” nanolithography. Science1999; 283(5402): 661−3.
[26]

Canelas DA, Herlihy KP, DeSimone JM. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol2009; 1(4): 391−404.
[27]

Key J, Leary JF. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomedicine2014; 9:711−26.
[28]

He X, Wang K, Cheng Z. In vivo near-infrared fluorescence imaging of cancer with nanoparticle-based probes. Wiley Interdiscip Rev Nanomed Nanobiotechnol2010; 2(4): 349−66.
[29]

He X, Gao J, Gambhir SS, Cheng Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol Med2010; 16(12): 574−83.
[30]

Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol2004; 22(1): 47−52.
[31]

Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Quantum dots for live cells, in vivo imaging, and diagnostics. Science2005; 307(5709): 538−44.
[32]

Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater2005; 4(6): 435−46.
[33]

Gao J, Chen K, Luong R, Bouley DM, Mao H, Qiao T, A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Lett2012; 12(1): 281−6.
[34]

Smith BR, Cheng Z, De A, Koh AL, Sinclair R, Gambhir SS. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett2008; 8(9): 2599−606.
[35]

Cai W, Hsu AR, Li ZB, Chen X. Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett2007; 2(6): 265−81.
[36]

Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J, microPET-based biodistribution of quantum dots in living mice. J Nucl Med2007; 48(9): 1511−8.
[37]

Schipper ML, Iyer G, Koh AL, Cheng Z, Ebenstein Y, Aharoni A, Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small2009; 5(1): 126−34.
[38]

Gao J, Chen K, Xie R, Xie J, Lee S, Cheng Z, Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. Small2010; 6(2): 256−61.
[39]

Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 2011; 32(8): 2141−8.
[40]

DeCoste SD, Farinelli W, Flotte T, Anderson RR. Dye-enhanced laser welding for skin closure. Lasers Surg Med1992; 12(1): 25−32.
[41]

Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano2011; 5(6): 4422−33.
[42]

Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small2009; 5(16): 1862−8.
[43]

Yan X, Niu G, Lin J, Jin AJ, Hu H, Tang Y, Enhanced fluorescence imaging guided photodynamic therapy of sinoporphyrin sodium loaded graphene oxide. Biomaterials2015; 42: 94−102.
[44]

Yan X, Hu H, Lin J, Jin AJ, Niu G, Zhang S, Optical and photoacoustic dual-modality imaging guided synergistic photodynamic/photothermal therapies. Nanoscale2015; 7(6): 2520−6.
[45]

Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials2011; 32(29): 7127−38.
[46]

Liu H, Zhang X, Xing B, Han P, Gambhir SS, Cheng Z. Radiation-luminescence-excited quantum dots for in vivo multiplexed optical imaging. Small2010; 6(10): 1087−91.
[47]

Yang Y, Shao Q, Deng R, Wang C, Teng X, Cheng K, In vitro and in vivo uncaging and bioluminescence imaging by using photocaged upconversion nanoparticles. Angew Chem Int Ed Engl2012; 51(13): 3125−9.
[48]

Mitchell GS, Gill RK, Boucher DL, Li C, Cherry SR. In vivo Cerenkov luminescence imaging: a new tool for molecular imaging. Philos Trans A Math Phys Eng Sci2011; 369(1955): 4605−19.
[49]

Carpenter CM, Sun C, Pratx G, Rao R, Xing L. Hybrid x-ray/optical luminescence imaging: characterization of experimental conditions. Med Phys2010; 37(8): 4011−8.
[50]

Pratx G, Carpenter CM, Sun C, Rao RP, Xing L. Tomographic molecular imaging of x-ray-excitable nanoparticles. Opt Lett2010; 35(20): 3345−7.
[51]

Pratx G, Carpenter CM, Sun C, Xing L. X-ray luminescence computed tomography via selective excitation: a feasibility study. IEEE Trans Med Imaging2010; 29(12): 1992−9.
[52]

Sun C, Pratx G, Carpenter CM, Liu H, Cheng Z, Gambhir SS, Synthesis and radioluminescence of PEGylated Eu(3+) -doped nanophosphors as bioimaging probes. Adv Mater2011; 23(24): H195−9.
[53]

Keren S, Zavaleta C, Cheng Z, de la Zerda A, Gheysens O, Gambhir SS. Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proc Natl Acad Sci USA2008; 105(15): 5844−9.
[54]

Zavaleta CL, Hartman KB, Miao Z, James ML, Kempen P, Thakor AS, Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging. Small2011; 7(15): 2232−40.
[55]

Jokerst JV, Miao Z, Zavaleta C, Cheng Z, Gambhir SS. Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor. Small2011; 7(5): 625−33.
[56]

Grinvald A, Lieke E, Frostig RD, Gilbert CD, Wiesel TN. Functional architecture of cortex revealed by optical imaging of intrinsic signals. Nature1986; 324(6095): 361−4.
[57]

He Y, Tang Z, Chen Z, Wan W, Li J. A novel photoacoustic tomography based on a time-resolved technique and an acoustic lens imaging system. Phys Med Biol2006; 51(10): 2671−80.
[58]

Wang LV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science2012; 335(6075): 1458−62.
[59]

Fan Q, Cheng K, Yang Z, Zhang R, Yang M, Hu X, Perylene-diimide-based nanoparticles as highly efficient photoacoustic agents for deep brain tumor imaging in living mice. Adv Mater2015; 27(5): 843−7.
[60]

Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol2005; 9(6): 674−9.
[61]

Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol2007; 2(1): 47−52.
[62]

De la Zerda A, Zavaleta C, Keren S, Vaithilingam S, Bodapati S, Liu Z, Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol2008; 3(9): 557−62.
[63]

De la Zerda A, Liu Z, Bodapati S, Teed R, Vaithilingam S, Khuri-Yakub BT, Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett2010; 10(6): 2168−72.
[64]

Ren G, Miao Z, Liu H, Jiang L, Limpa-Amara N, Mahmood A, Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med2009; 50(10): 1692−9.
[65]

Cheng Z, Mahmood A, Li H, Davison A, Jones AG. [99mTcOAADT]-(CH2)2-NEt2: a potential small-molecule single-photon emission computed tomography probe for imaging metastatic melanoma. Cancer Res2005; 65(12): 4979−86.
[66]

Zhang R, Fan Q, Yang M, Cheng K, Lu X, Zhang L, Engineering melanin nanoparticles as an efficient drug-delivery system for imaging-guided chemotherapy. Adv Mater2015; 27(34): 5063−9.
[67]

Yang M, Fan Q, Zhang R, Cheng K, Yan J, Pan D, Dragon fruit-like biocage as an iron trapping nanoplatform for high efficiency targeted cancer multimodality imaging. Biomaterials2015; 69: 30−7.
[68]

Bloch SH, Dayton PA, Ferrara KW. Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag2004; 23(5): 18−29.
[69]

Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci USA2008; 105(21): 7570−5.
[70]

Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci USA2013; 110(29): 11751−6.
[71]

Kiessling F, Huppert J, Zhang C, Jayapaul J, Zwick S, Woenne EC, RGD-labeled USPIO inhibits adhesion and endocytotic activity of ανβ3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology2009; 253(2): 462−9.
[72]

Anderson CR, Hu X, Zhang H, Tlaxca J, Declèves AE, Houghtaling R, Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol2011; 46(4): 215−24.
[73]

Yan F, Xu X, Chen Y, Deng Z, Liu H, Xu J, A lipopeptide-based ανβ3 integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis. Ultrasound Med Biol2015; 41(10): 2765−73.
[74]

Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med2010; 51(3): 433−40.
[75]

Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, Rosenberg J, Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology2008; 248(3): 936−44.
[76]

Chavanpatil MD, Khdair A, Panyam J. Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol2006; 6(9−10): 2651−63.
[77]

Shamsi K, Balzer T, Saini S, Ros PR, Nelson RC, Carter EC, Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging. Radiology1998; 206(2): 365−71.
[78]

Reimer P, Jähnke N, Fiebich M, Schima W, Deckers F, Marx C, Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology2000; 217(1): 152−8.
[79]

Bu L, Xie J, Chen K, Huang J, Aguilar ZP, Wang A, Assessment and comparison of magnetic nanoparticles as MRI contrast agents in a rodent model of human hepatocellular carcinoma. Contrast Media Mol Imaging2012; 7(4): 363−72.
[80]

de Marco G, Bogdanov A, Marecos E, Moore A, Simonova M, Weissleder R. MR imaging of gene delivery to the central nervous system with an artificial vector. Radiology1998; 208(1): 65−71.
[81]

Gupta AK, Curtis AS. Surface modified superparamagnetic nanoparticles for drug delivery: interaction studies with human fibroblasts in culture. J Mater Sci Mater Med2004; 15(4): 493−6.
[82]

Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett2012; 7(1): 144.
[83]

Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng2006; 34(1): 23−38.
[84]

Cheng K, Yang M, Zhang R, Qin C, Su X, Cheng Z. Hybrid nanotrimers for dual T1 and T2-weighted magnetic resonance imaging. ACS Nano2014; 8(10): 9884−96.
[85]

Yoffe S, Leshuk T, Everett P, Gu F. Superparamagnetic iron oxide nanoparticles (SPIONs): synthesis and surface modification techniques for use with MRI and other biomedical applications. Curr Pharm Des2013; 19(3): 493−509.
[86]

Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials2005; 26(18): 3995−4021.
[87]

Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl2008; 47(29): 5362−5.
[88]

Phelps ME, Hoffman EJ, Huang SC, Ter-Pogossian MM. Effect of positron range on spatial resolution. J Nucl Med1975; 16(7): 649−52.
[89]

Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res2009; 42(7): 832−41.
[90]

Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS. Radiometals for combined imaging and therapy. Chem Rev2013; 113(2): 858−83.
[91]

Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev2010; 110(5): 2858−902.
[92]

Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med2007; 48(11): 1862−70.
[93]

Kirchner C, Liedl T, Kudera S, Pellegrino T, Muñoz Javier A, Gaub HE, Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett2005; 5(2): 331−8.
[94]

Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett2006; 6(4): 669−76.
[95]

Chen K, Li ZB, Wang H, Cai W, Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging2008; 35(12): 2235−44.
[96]

Nahrendorf M, Zhang H, Hembrador S, Panizzi P, SosnovikDE, Aikawa E, Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation2008; 117(3): 379−87.
[97]

Nahrendorf M, Keliher E, Marinelli B, Waterman P, Feruglio PF, Fexon L, Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci USA2010; 107(17): 7910−5.
[98]

Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials2011; 32(17): 4151−60.
[99]

Liu TW, Macdonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano2013; 7(5): 4221−32.
[100]

Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep2014; 4: 5080.
[101]

Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med2003; 44(8): 1271−81.
[102]

Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol2009; 36(7): 729−39.
[103]

Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol Imaging2010; 9(1): 1−20.
[104]

Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab. PLoS ONE2010; 5(1): e8859.
[105]

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med2010; 51(8): 1293−300.
[106]

Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomedicine2010; 5: 783−802.
[107]

Lee J, Lee TS, Ryu J, Hong S, Kang M, Im K, RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med2013; 54(1): 96−103.
[108]

Lijowski M, Caruthers S, Hu G, Zhang H, Scott MJ, Williams T, High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol2009; 44(1): 15−22.
[109]

Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Imaging of Vx-2 rabbit tumors with ανβ3-integrin-targeted 111In nanoparticles. Int J Cancer2007; 120(9): 1951−7.
[110]

Yang M, Cheng K, Qi S, Liu H, Jiang Y, Jiang H, Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. Biomaterials2013; 34(11): 2796−806.

Funding

()

PDF (2399KB)

4264

Accesses

0

Citation

Detail
Sections
Recommended

/

〈 〉